BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today.
Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.
Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
831 articles about BioMarin Pharmaceutical Inc.
-
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
1/3/2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024 , at 10:30 am PT / 1:30 pm ET , in San Francisco, California.
-
It wasn't a merry end to 2023 for Amgen or Zealand Pharma, which received Complete Response Letters for Lumakras and for dasiglucagon in congenital hyperinsulinism.
-
Activist investor Elliott Investment Management has struck a deal with BioMarin and will add three people to its board of directors with a new stake in the company.
-
BioMarin Announces Governance Enhancements and Value Creation Initiatives
12/20/2023
BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced several initiatives to enhance corporate governance and long-term shareholder value creation.
-
As the end of 2023 approaches, hiring has slowed down further and in our most recent survey, fewer companies report that they are actively recruiting.
-
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
11/28/2023
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A.
-
Activist hedge fund investor Elliott Investment Management has bought over a $1 billion stake in BioMarin as the biotech grapples with a leadership change and disappointing sales of its hemophilia A gene therapy.
-
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
11/1/2023
BioMarin Pharmaceutical Inc. announced financial results for the nine months and third quarter ended September 30, 2023.
-
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
11/1/2023
BioMarin Pharmaceutical Inc. announced that Alexander Hardy has been named president and chief executive officer, succeeding Jean-Jacques Bienaimé, who will retire as chairman and CEO effective December 1, 2023.
-
The label for the achondroplasia drug, which promotes endochondral bone growth, now covers children under five years of age with the rare genetic disease causing the most common form of dwarfism.
-
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
10/20/2023
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) to increase linear growth in pediatric patients with achondroplasia with open epiphyses (growth plates).
-
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
10/17/2023
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m. ET to discuss third-quarter 2023 financial results and provide a general business update.
-
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
9/21/2023
BioMarin Pharmaceutical Inc. today announced that new data on VOXZOGO ® (vosoritide) in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting in The Hague, Netherlands.
-
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
9/11/2023
BioMarin Pharmaceutical Inc. will update the investor community on the company's research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and ROCTAVIAN.
-
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
9/6/2023
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023.
-
BioMarin to Participate in Three Upcoming Investor Conferences
9/5/2023
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September.
-
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
8/30/2023
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that an individual in Germany with severe hemophilia A was treated with ROCTAVIAN® (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe.
-
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
7/31/2023
BioMarin Pharmaceutical Inc. announced financial results for the six months and second quarter ended June 30, 2023.
-
The first half of this year saw milestone approvals for rare disease therapies, and the FDA has several more such decisions on its calendar in the second half of 2023.
-
The FDA’s CBER approved nine novel therapies in the first half of 2023, with several more high-profile decisions on deck for the second half of the year.